TNGX — Tango Therapeutics, Inc.

Is TNGX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Tango Therapeutics, Inc. (TNGX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $22.11. The rating moved from Overbought to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Tango Therapeutics is a small-cap oncology-focused company whose valuation is driven primarily by the success of its clinical programs and any partnership or licensing activity. The firm’s targeted approach and potential for high-impact readouts provide meaningful upside if early- to mid-stage data are positive or if strategic collaborations materialize. At the same time, the company likely carries typical biotech balance-sheet and dilution risk, and its shares remain sensitive to binary trial outcomes and broader market liquidity. Absent definitive revenue streams, near-term performance will depend on clinical milestones, financing execution, and sector flows into selective growth names.

Key factors

  • Pipeline leverage to targeted oncology and synthetic lethality approaches with potential high-value clinical readouts
  • Large upside tied to successful clinical data or partnership/licensing deals given company’s small-cap biotech profile
  • Favorable intraday market tone toward selective growth names and sector rotation that can support momentum into catalysts
  • Strategic optionality for M&A or collaborations as large-cap pharma continues consolidating specialty franchises
  • Limited near-term product revenue, allowing upside to be driven by binary clinical/regulatory outcomes which can re-rate the equity

Risks

  • Binary clinical and regulatory risk — negative readouts could materially reduce valuation
  • Likely ongoing cash burn with potential need for financing that could dilute shareholders or pressure the share price
  • Competitive risk from larger, better-capitalized oncology franchises and overlapping programs from big pharma
  • Reimbursement and payer pressures in specialty therapeutics or downstream clinical adoption challenges
  • Macroeconomic or risk-off moves could disproportionately impact small-cap biotech liquidity and multiples
  • Limited public/analyst coverage and absent social sentiment signals increase dependence on company-disclosed catalysts for price action

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for TNGX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.